IS6973A - Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma - Google Patents

Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma

Info

Publication number: IS6973A
Authority: IS; Iceland
Prior art keywords: methyl; hydrogen; trifluoromethyl; fluorine; aminosulphonyl
Prior art date: 2001-04-06

Application number

IS6973A

Other languages

English (en)

Inventor

Rosa Cuberes-Altisent María

María Berrocal-Romero Juana

Montserrat Contijoch-Llobet María

Frigola-Constansa Jordi

Original Assignee

Laboratorios Del Dr. Esteve, S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-06

Filing date

2003-10-03

Publication date

2003-10-03

2003-10-03 Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.

2003-10-03 Publication of IS6973A publication Critical patent/IS6973A/is

Links

150000003219 pyrazolines Chemical class 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title 1
229940126601 medicinal product Drugs 0.000 title 1
230000002265 prevention Effects 0.000 title 1
230000002062 proliferating effect Effects 0.000 title 1
-1 methoxy, trifluoromethoxy, methylsulphonyl Chemical group 0.000 abstract 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 10
229910052739 hydrogen Inorganic materials 0.000 abstract 9
239000001257 hydrogen Substances 0.000 abstract 9
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 9
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 8
229910052731 fluorine Inorganic materials 0.000 abstract 7
239000011737 fluorine Substances 0.000 abstract 7
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 5
229910052801 chlorine Inorganic materials 0.000 abstract 5
239000000460 chlorine Substances 0.000 abstract 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
125000001424 substituent group Chemical group 0.000 abstract 2
125000005599 alkyl carboxylate group Chemical group 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
150000003857 carboxamides Chemical class 0.000 abstract 1
150000001732 carboxylic acid derivatives Chemical group 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000001153 fluoro group Chemical group F* 0.000 abstract 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IS6973A 2001-04-06 2003-10-03 Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma IS6973A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES200100818A ES2174757B1 (es)	2001-04-06	2001-04-06	Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
PCT/ES2002/000137 WO2002080909A1 (es)	2001-04-06	2002-03-21	Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares

Publications (1)

Publication Number	Publication Date
IS6973A true IS6973A (is)	2003-10-03

Family

ID=8497370

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6973A IS6973A (is)	2001-04-06	2003-10-03	Notkun pýrasólínafleiða í framleiðslu á lyfi til að fyrirbyggja og/eða meðhöndla frumufjölgunarsjúkdóma

Country Status (26)

Country	Link
US (1)	US20040034082A1 (is)
EP (2)	EP1516621A3 (is)
JP (1)	JP4451599B2 (is)
KR (1)	KR20040025912A (is)
CN (2)	CN1299682C (is)
AT (1)	ATE326966T1 (is)
AU (1)	AU2002246152B2 (is)
BR (1)	BR0208805A (is)
CA (1)	CA2442974C (is)
CY (1)	CY1105523T1 (is)
DE (1)	DE60211681T2 (is)
DK (1)	DK1384477T3 (is)
ES (2)	ES2174757B1 (is)
HU (1)	HUP0400918A3 (is)
IL (1)	IL158269A0 (is)
IS (1)	IS6973A (is)
MA (1)	MA27019A1 (is)
MX (1)	MXPA03009124A (is)
NO (1)	NO20034470L (is)
NZ (1)	NZ529304A (is)
PL (1)	PL365220A1 (is)
PT (1)	PT1384477E (is)
RU (1)	RU2305545C2 (is)
UA (1)	UA75402C2 (is)
WO (1)	WO2002080909A1 (is)
ZA (1)	ZA200308626B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2238923B1 (es) *	2004-02-16	2006-11-01	Laboratorios Del Dr. Esteve, S.A.	Nuevos derivados pirazolinicos sustituidos.
KR20070044799A (ko) *	2004-02-16	2007-04-30	라보라토리오스 델 드라. 에스테브.에스.에이.	암 치료에 유용한 피라졸린 유도체
TW200533657A (en) *	2004-02-17	2005-10-16	Esteve Labor Dr	Substituted pyrazoline compounds, their preparation and use as medicaments
US7998996B2 (en)	2004-02-17	2011-08-16	Laboratorios Del Dr. Esteve S.A.	Substituted pyrazoline compounds for reducing triglycerides in blood
EP1637522A1 (en) *	2004-09-16	2006-03-22	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds for reducing triglycerides in blood
BRPI0507790A (pt) *	2004-02-17	2007-07-17	Esteve Labor Dr	composto de pirazolina substituìda, processo para a sua manufatura, medicamentos e seus usos
ES2327379B1 (es) *	2005-07-15	2010-05-28	Laboratorios Del Dr. Esteve, S.A.	Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
WO2007009707A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
EP1749527A1 (en) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1849784A1 (en) *	2006-04-26	2007-10-31	Laboratorios Del Dr. Esteve, S.A.	Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
ES2334967B1 (es) *	2005-07-15	2010-10-21	Laboratorios Del Dr. Esteve, S.A.	Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
WO2007009699A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A	Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009702A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743889A1 (en) *	2005-07-15	2007-01-17	Laboratorios del Dr. Esteve S.A.	Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1743890A1 (en)	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1749525A1 (en) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Combination of substituted pyrazolines and anti-addictive agent
WO2007009701A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
WO2007009693A1 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr.Esteve, S.A	Combination of a substituted pyrazoline compound and a drug used in food-related disorders
EP1849776A1 (en) *	2006-04-26	2007-10-31	Laboratorios Del Dr. Esteve, S.A.	Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
EP1746090A1 (en) *	2005-07-15	2007-01-24	Laboratorios del Dr. Esteve S.A.	Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
WO2007009700A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1743637A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1743643A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	New formulations of substituted pyrazoline compounds
ES2326724B1 (es) *	2005-07-15	2010-05-11	Laboratorios Del Dr. Esteve, S.A.	Nuevas formulaciones de compuestos de pirazolina sustituidos.
US7897589B2 (en)	2005-07-15	2011-03-01	Laboratorios Del Dr. Esteve, S.A.	Substituted pyrazoline compounds, their preparation and use as medicaments
ES2326725B1 (es) *	2005-07-15	2010-05-11	Laboratorios Del Dr. Esteve, S.A.	Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
EP1749526A1 (en) *	2005-07-15	2007-02-07	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
EP1743636A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Combination of a substituted pyrazoline compound and a drug used in food-related disorders
EP1743639A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
WO2007009691A2 (en) *	2005-07-15	2007-01-25	Laboratorios Del Dr. Esteve, S.A.	Combination of substituted pyrazolines and anti -addictive agent
EP1743642A1 (en) *	2005-07-15	2007-01-17	Laboratorios Del Dr. Esteve, S.A.	Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
KR101457637B1 (ko) *	2012-10-24	2014-11-20	건국대학교 산학협력단	디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
CN103664785A (zh) *	2013-11-04	2014-03-26	南京大学	一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
US20230082841A1 (en) *	2021-09-14	2023-03-16	Maverick Gold (NV) LLC	Methods and systems for titling and trading alternative reserves

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0674624T3 (da) *	1992-12-17	1999-09-13	Pfizer	Pyrazoler med CRF-antagonistisk aktivitet
CA2277954A1 (en) *	1993-11-30	1995-06-08	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5604253A (en) *	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5972986A (en) *	1997-10-14	1999-10-26	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2137138B1 (es) *	1998-05-29	2000-09-16	Esteve Labor Dr	Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
KR100796851B1 (ko) *	1999-06-16	2008-01-22	템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션	사이클록시게나아제-2의 억제제로서 1-(4-설파밀아릴)-3-치환형-5-아릴-2-피라졸린

2001
- 2001-04-06 ES ES200100818A patent/ES2174757B1/es not_active Expired - Fee Related
2002
- 2002-03-21 DE DE60211681T patent/DE60211681T2/de not_active Expired - Lifetime
- 2002-03-21 BR BR0208805-3A patent/BR0208805A/pt not_active IP Right Cessation
- 2002-03-21 PT PT02714233T patent/PT1384477E/pt unknown
- 2002-03-21 ES ES02714233T patent/ES2264723T3/es not_active Expired - Lifetime
- 2002-03-21 PL PL02365220A patent/PL365220A1/xx not_active Application Discontinuation
- 2002-03-21 CA CA2442974A patent/CA2442974C/en not_active Expired - Fee Related
- 2002-03-21 CN CNB028098935A patent/CN1299682C/zh not_active Expired - Fee Related
- 2002-03-21 MX MXPA03009124A patent/MXPA03009124A/es active IP Right Grant
- 2002-03-21 JP JP2002578948A patent/JP4451599B2/ja not_active Expired - Fee Related
- 2002-03-21 HU HU0400918A patent/HUP0400918A3/hu unknown
- 2002-03-21 WO PCT/ES2002/000137 patent/WO2002080909A1/es not_active Ceased
- 2002-03-21 ZA ZA200308626A patent/ZA200308626B/en unknown
- 2002-03-21 AT AT02714233T patent/ATE326966T1/de not_active IP Right Cessation
- 2002-03-21 RU RU2003132457/15A patent/RU2305545C2/ru not_active IP Right Cessation
- 2002-03-21 EP EP04030751A patent/EP1516621A3/en not_active Withdrawn
- 2002-03-21 UA UA2003119998A patent/UA75402C2/uk unknown
- 2002-03-21 DK DK02714233T patent/DK1384477T3/da active
- 2002-03-21 IL IL15826902A patent/IL158269A0/xx unknown
- 2002-03-21 CN CNA2005100713090A patent/CN1698602A/zh active Pending
- 2002-03-21 NZ NZ529304A patent/NZ529304A/en unknown
- 2002-03-21 US US10/312,193 patent/US20040034082A1/en not_active Abandoned
- 2002-03-21 AU AU2002246152A patent/AU2002246152B2/en not_active Ceased
- 2002-03-21 EP EP02714233A patent/EP1384477B1/en not_active Expired - Lifetime
- 2002-03-21 KR KR10-2003-7013062A patent/KR20040025912A/ko not_active Ceased
2003
- 2003-10-03 IS IS6973A patent/IS6973A/is unknown
- 2003-10-06 NO NO20034470A patent/NO20034470L/no not_active Application Discontinuation
- 2003-11-05 MA MA27382A patent/MA27019A1/fr unknown
2006
- 2006-08-03 CY CY20061101088T patent/CY1105523T1/el unknown

Also Published As

Publication number	Publication date
DK1384477T3 (da)	2006-08-21
AU2002246152B2 (en)	2007-05-31
ATE326966T1 (de)	2006-06-15
ES2174757A1 (es)	2002-11-01
KR20040025912A (ko)	2004-03-26
CN1698602A (zh)	2005-11-23
CY1105523T1 (el)	2010-07-28
US20040034082A1 (en)	2004-02-19
EP1516621A3 (en)	2005-05-04
HK1067311A1 (en)	2005-04-08
MA27019A1 (fr)	2004-12-20
CN1299682C (zh)	2007-02-14
JP2004525166A (ja)	2004-08-19
NZ529304A (en)	2006-02-24
CA2442974A1 (en)	2002-10-17
UA75402C2 (en)	2006-04-17
EP1384477A1 (en)	2004-01-28
WO2002080909A1 (es)	2002-10-17
PT1384477E (pt)	2006-09-29
HUP0400918A2 (hu)	2004-07-28
ES2174757B1 (es)	2003-11-01
CA2442974C (en)	2010-02-23
JP4451599B2 (ja)	2010-04-14
DE60211681D1 (de)	2006-06-29
IL158269A0 (en)	2004-05-12
NO20034470L (no)	2003-12-05
EP1384477B1 (en)	2006-05-24
RU2003132457A (ru)	2005-04-10
CN1509171A (zh)	2004-06-30
MXPA03009124A (es)	2005-04-11
PL365220A1 (en)	2004-12-27
HUP0400918A3 (en)	2004-10-28
NO20034470D0 (no)	2003-10-06
DE60211681T2 (de)	2007-05-16
EP1516621A2 (en)	2005-03-23
ES2264723T3 (es)	2007-01-16
ZA200308626B (en)	2004-11-05
BR0208805A (pt)	2004-07-13
RU2305545C2 (ru)	2007-09-10

Publication	Publication Date	Title
NO20034470L (no)	2003-12-05	Anvendelse av pyrazolin-derivater ved fremstilling av et medikament for forebygging og/eller behandling av proliferasjonssykdommer
NZ508990A (en)	2002-12-20	Pyrazoline derivatives, their preparation and application as medicaments
DK1109813T3 (da)	2004-12-20	Pyrroloindoler, pyridoindoler og azepinoindoler som 5-HT2C-agonister
DE69915519D1 (en)	2004-04-15	Pyrazolopyridine
MY126951A (en)	2006-11-30	Beta2-adrenoceptor agonists
NZ509318A (en)	2002-10-25	Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
DK0745596T3 (da)	1999-11-08	Heteroaromatiske oxazolforbindelser og anvendelse deraf
MXPA05004779A (es)	2005-07-22	Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis.
MY119689A (en)	2005-06-30	Pyrazolopyridine derivatives
PE20030332A1 (es)	2003-04-05	Terapia de combinacion para el tratamiento del cancer
PT1202954E (pt)	2004-02-27	Novas aminobenzofenonas
HUP9904086A2 (hu)	2000-11-28	4-es Helyzetben szubsztituált piperidinszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
MXPA04004307A (es)	2004-08-11	Derivados de fenoxi-n-`4-(1,1-dioxoisotiazolidin-2-il)fenil-valeramida y otros compuestos como inhibidores del factor de coagulacion xa para el tratamiento de enfermedades tromboembolicas y tumores.
MXPA03002914A (es)	2003-09-10	Compuestos quimicos.
DK1049672T3 (da)	2004-01-19	Azetidincarboxamid-derivater til behandling af CNS-lidelser
DK1049670T3 (da)	2002-11-11	Azetidincarboxamidderivater til behandling af CNS-lidelser